• Roivant Launches Respivant Sciences americanpharmaceuticalreview
    September 18, 2018
    Roivant Sciences announced the launch of Respivant Sciences, a biopharmaceutical company focused on the lives of patients suffering from serious respiratory diseases...
  • PhaseBio nets $34M to advance Brilinta reversal agent, PAH drug fiercebiotech
    September 06, 2018
    PhaseBio is using its ELP platform to extend the half-life of proteins, peptides and other large molecules to create injectable drugs that can be administered less frequently.
PharmaSources Customer Service